Heart failure affects millions of patients annually and heart failure with preserved ejection fraction is becoming the predominant subtype. Accurately diagnosing and evaluating these patients can be difficult due to high heterogeneity. Cardiac fibrosis is a common trait in heart failure patients. The extracellular matrix remodeling can be assessed by measuring circulating neo-epitopes of formation and degradation. It is becoming increasingly evident that these specific biomarkers improve both diagnostics and prognostics in patient assessment.
More about our cardiac biomarkers for Heart Failure
Cardiomyopathy management has been based solely on the morphological and functional changes of the heart for a long time. The last decades of imaging evolution and genetic testing have contributed immensely to disease diagnosis and management. Heart failure biomarkers including natriuretic peptides and troponin isoforms have also been used to assess cardiac stress and cardiomyocyte cell death. However, heart failure is often the endpoint of cardiomyopathies hence there is an unmet need for circulating biomarkers for early diagnosis and/or prognostic ability
More about our cardiac biomarkers for Cardiomyopathies
In atherosclerosis, plaque formation leads to stiffer arteries with increased hypertension. The extracellular matrix composition in atherosclerotic plaques is fragile, and plaque rupture can lead to stroke and myocardial infarctions. Myocardial infarction leads to tissue damage in the heart, which initiates a fibrotic tissue healing process. Understanding this dynamic and rapid extracellular matrix remodeling by assessing the formation and degradation of neo-epitopes can help identify patients at risk of adverse outcomes.
More about our cardiac biomarkers for Atherosclerosis and Myocardial Infarction
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
